ProCE Banner Activity

Answers to Frequently Asked Questions on Optimizing CLL Management With BTK Inhibitors

Clinical Thought
Read expert answers to key questions asked by an audience of healthcare professionals during a live CCO webinar regarding the expert management of CLL/SLL including insights on clinical considerations when recommending BTK inhibitors.

Released: May 21, 2021

Expiration: May 20, 2022

No longer available for credit.

Share

Faculty

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics AbbVie

Faculty Disclosure

Primary Author

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Pharmacyclics, and TG Therapeutics and consulting fees from AbbVie, AstraZeneca, BeiGene, Genentech, Pharmacyclics, and TG Therapeutics.

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Pharmacyclics, and TG Therapeutics and consulting fees from AbbVie, AstraZeneca, BeiGene, Genentech, Pharmacyclics, and TG Therapeutics.